| Project/Area Number |
25861289
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Showa University |
|---|
Principal Investigator |
Watanabe Jun 昭和大学, 遺伝子組換え実験室, 助教 (50649069)
|
|---|
| Research Collaborator |
SHIODA Seiji
Ohtaki Hirokazu
Darwin Prockop
Ashok Shetty
|
|---|
| Project Period (FY) |
2013-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 頭部外傷 / 骨髄由来間葉系幹細胞 / 高次脳機能障害 / 血液脳関門 / アストロサイト / 高次脳機能要害 / 骨髄間葉系幹細胞 / TSG-6 |
|---|
| Outline of Final Research Achievements |
Traumatic brain injury (TBI) causes multiple long-term defects including a loss of working memory that is frequently incapacitating. Administrations of mesenchymal stem/stromal cells (MSCs) previously produced beneficial effects in models of TBI as well as other disease models. In several models, the beneficial effects were explained by the MSCs being activated to express TSG-6. In a mouse model of TBI, we found the intravenous human MSCs or TSG-6 decreased the blood brain barrier leakage. In this time, the expression of GFAP was significantly increased. Administration of TSG-6 also decreased the lesion size at 2 weeks. Importantly, the acute administration of TSG-6 within 24 h of TBI was followed 6 to 10 weeks later by improvements in memory, depressive-like behavior and the number of newly born-neurons. The data suggested that acute administration of TSG-6 may be an effective therapy for decreasing some of the long-term consequences of TBI.
|
